Founded in 2001, TaiGen Biotechnology Co., Ltd. (“TaiGen Taiwan” or “TaiGen”) is
a research-based and product-driven pharmaceutical company engaging in the
development of novel therapeutics for infectious diseases, cancer and
diabetes-related complications. TaiGen has a wholly-owned Beijing subsidiary
with a proven capacity to conduct clinical trials and related registrations.
There are 77 FTEs including 80% R&D staffs in Taipei and Beijing offices.
In 2008, TaiGen Taiwan completed a share swap with TaiGen Biopharmaceuticals
Holdings Limited (“TaiGen Cayman” or “TaiGen”), and has become a fully owned
subsidiary of TaiGen Cayman. TaiGen Cayman will be the legal entity for TaiGen’s
IPO; as of Feb. 2013, there are approx. 633 million shares issued and
outstanding, each with par value of US$0.001.
TaiGen has raised a total of US$124 million since its inception; principle shareholders
include Taiwan’s National Development Fund, Yuen Foong Yu (YFY) Group, China
Development Industrial Bank, Shin Kong Life Insurance, Cathay Life Insurance,
China Steel Corporation, Taiwan Sugar Corporation, Yao-Hwa Glass Management
Commission, and Taiwan Global BioFund.
TaiGen has built a fully-integrated pharmaceutical company by pursuing a
business strategy that capitalizes on the management team's extensive expertise
in drug discovery, development, global regulatory approval processes, and
commercialization in China. Senior executives at TaiGen were recruited from both
major pharmaceutical/biotech companies in the West as well as from Asian-based
multinational companies. This unique expertise allows the company to focus on
in-licensing innovative drugs targeting Asian-prevalent diseases to
complement its own internal research programs as well as to partner its organic
drug development programs. In addition, TaiGen has formed marketing alliances to
capture the rapidly-expanding Asian pharmaceutical market.
TaiGen's current pipeline includes "first-in-class" and "best-in-class" products
with worldwide IP rights.